PE20201150A1 - Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas - Google Patents
Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismasInfo
- Publication number
- PE20201150A1 PE20201150A1 PE2020000593A PE2020000593A PE20201150A1 PE 20201150 A1 PE20201150 A1 PE 20201150A1 PE 2020000593 A PE2020000593 A PE 2020000593A PE 2020000593 A PE2020000593 A PE 2020000593A PE 20201150 A1 PE20201150 A1 PE 20201150A1
- Authority
- PE
- Peru
- Prior art keywords
- isoxazoline
- present
- compound
- haloalkyl
- microns
- Prior art date
Links
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical group C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 isoxazoline compound Chemical class 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004498 fluralaner Drugs 0.000 abstract 1
- 125000004969 haloethyl group Chemical group 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 abstract 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 abstract 1
- 229960004816 moxidectin Drugs 0.000 abstract 1
- 230000000590 parasiticidal effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica inyectable que comprende: a) particulas de un compuesto de isoxazolina de formula (I), donde: R1 es halogeno, CF3, OCF3 CN; n es 0 a 3; R2 es haloalquilo C1-C3, CF3 o CF2Cl; T es un anillo de 5 o 6 miembros, opcionalmente sustituido por Y, donde Y es metilo, halometilo, halogeno, entre otros; Q es X-NR3R4, NR5-NR6-X-R3, entre otros; X es CH2, CH(CH3), entre otros; R3 es hidrogeno, metilo, haloetilo, entre otros; R4 es hidrogeno, etilo, metoximetilo, entre otros; R5 y R6 son H, alquilo o haloalquilo, y b) un excipiente farmaceuticamente aceptable; en donde el compuesto de isoxazolina tiene una distribucion de tamano de particula ponderada en volumen D50 de 50 micras a 150 micras. Un compuesto de isoxazolina preferido es fluralaner, presente en una cantidad entre 5% p/v a 50% p/v; adicionalmente, dicha composicion comprende un compuesto parasiticida, tal como milbemicina o moxidectina, presente en una cantidad entre 0.1% p/v a 1.0% p/v. Tambien se refiere a un kit. Dicha composicion inyectable de isoxazolina presenta eficacia a largo plazo contra parasitos y un riesgo reducido de irritacion en el sitio de inyeccion, siendo util en la prevencion o tratamiento de una infestion de parasitos en animales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582381P | 2017-11-07 | 2017-11-07 | |
| US201762608904P | 2017-12-21 | 2017-12-21 | |
| PCT/EP2018/080226 WO2019091936A1 (en) | 2017-11-07 | 2018-11-06 | Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201150A1 true PE20201150A1 (es) | 2020-10-26 |
Family
ID=74717047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000593A PE20201150A1 (es) | 2017-11-07 | 2018-11-06 | Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210177808A1 (es) |
| EP (2) | EP4316522A3 (es) |
| JP (1) | JP7269927B2 (es) |
| KR (2) | KR102677903B1 (es) |
| CN (2) | CN118576555A (es) |
| AU (2) | AU2018363682B2 (es) |
| BR (2) | BR122023023401A2 (es) |
| CA (1) | CA3081646C (es) |
| CL (1) | CL2020001173A1 (es) |
| CO (1) | CO2020006257A2 (es) |
| DK (1) | DK3707128T3 (es) |
| ES (1) | ES2970570T3 (es) |
| FI (1) | FI3707128T3 (es) |
| IL (1) | IL274065B2 (es) |
| MX (1) | MX2020004694A (es) |
| NZ (1) | NZ764055A (es) |
| PE (1) | PE20201150A1 (es) |
| PH (1) | PH12020550555A1 (es) |
| UA (1) | UA127456C2 (es) |
| WO (1) | WO2019091936A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7446222B2 (ja) | 2017-11-07 | 2024-03-08 | インターベット インターナショナル ベー． フェー． | 大きいサイズのイソキサゾリン粒子の調製方法 |
| US20220125798A1 (en) * | 2019-03-06 | 2022-04-28 | Zoetis Services Llc | Ready-to-use injectable formulations |
| US20220354828A1 (en) * | 2019-10-01 | 2022-11-10 | Shilpa Medicare Ltd | Controlled release injectable ondansetron formulations |
| IL298259B1 (en) * | 2020-05-20 | 2024-08-01 | Intervet Int Bv | Injectable pharmaceutical compositions and uses thereof |
| CN114306231B (zh) * | 2021-12-29 | 2023-03-24 | 天津市中升挑战生物科技有限公司 | 一种氟雷拉纳杀虫剂及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740421A (en) | 1966-09-19 | 1973-06-19 | Basf Wyandotte Corp | Polyoxyethylene-polyoxypropylene aqueous gels |
| SI1731512T1 (sl) * | 2004-03-05 | 2015-01-30 | Nissan Chemical Industries, Ltd. | Z izoksazolinom substituirana benzamidna spojina in sredstvo za uravnavanje škodljivih organizmov |
| TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| US20100311655A1 (en) * | 2007-06-07 | 2010-12-09 | Mdrna, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| BRPI0810929B8 (pt) | 2007-06-27 | 2022-12-06 | Du Pont | uso de um composto de fórmula 1 |
| TWI556741B (zh) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| JP5365807B2 (ja) | 2007-11-12 | 2013-12-11 | 日産化学工業株式会社 | 光学活性イソキサゾリン化合物の触媒的不斉合成方法 |
| TWI411395B (zh) | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
| WO2010079077A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
| NZ593135A (en) | 2008-12-19 | 2013-04-26 | Novartis Ag | Isoxazoline derivatives and their use as pesticide |
| EP2453870A2 (en) * | 2009-06-24 | 2012-05-23 | MSD Oss B.V. | Injectable formulations containing asenapine and method of treatment using same |
| JP5679102B2 (ja) | 2009-08-03 | 2015-03-04 | 日産化学工業株式会社 | ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法 |
| TWI487486B (zh) | 2009-12-01 | 2015-06-11 | Syngenta Participations Ag | 以異唑啉衍生物為主之殺蟲化合物 |
| RS54772B1 (sr) | 2009-12-17 | 2016-10-31 | Merial Sas | Antiparazitska jedinjenja dihidroazola i kompozicije koje ih sadrže |
| MX2012011549A (es) | 2010-04-08 | 2013-01-29 | Ah Usa 42 Llc | Derivados de 3,5-difenil-isoxazolina sustituida como insecticidas y acaricidas. |
| HUE028501T2 (en) * | 2010-05-27 | 2016-12-28 | Du Pont | 4- [5- [3-Chloro-5- (trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [(2.2, 2-Trifluoroethyl) amino] ethyl] -1-naphthalenecarboxamide crystalline form |
| CN105579029B (zh) | 2013-09-30 | 2019-03-05 | 硕腾服务有限责任公司 | 长效螺异恶唑啉制剂 |
| MX2016008118A (es) * | 2013-12-20 | 2016-09-16 | Intervet Int Bv | Composiciones de isoxazolina y uso de las mismas en la prevencion o tratamiento de infestaciones parasitarias en animales. |
| UY36570A (es) * | 2015-02-26 | 2016-10-31 | Merial Inc | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas |
| JP6824900B2 (ja) | 2015-04-08 | 2021-02-03 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | イソオキサゾリン活性薬剤を含む延長放出注射製剤、方法及びその使用 |
| NZ742888A (en) * | 2015-12-22 | 2024-07-26 | Intervet Int B V | Injectable formulation of a macrocyclic lactone and levamisole |
| UY37137A (es) | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
| JP7446222B2 (ja) * | 2017-11-07 | 2024-03-08 | インターベット インターナショナル ベー． フェー． | 大きいサイズのイソキサゾリン粒子の調製方法 |
| AU2020268618A1 (en) * | 2019-05-03 | 2021-11-04 | Intervet International B.V. | Injectable pharmaceutical compositions and uses thereof |
-
2018
- 2018-11-06 KR KR1020237039804A patent/KR102677903B1/ko active IP Right Grant
- 2018-11-06 CN CN202410624345.8A patent/CN118576555A/zh active Pending
- 2018-11-06 ES ES18799511T patent/ES2970570T3/es active Active
- 2018-11-06 PE PE2020000593A patent/PE20201150A1/es unknown
- 2018-11-06 IL IL274065A patent/IL274065B2/en unknown
- 2018-11-06 NZ NZ764055A patent/NZ764055A/en unknown
- 2018-11-06 BR BR122023023401-4A patent/BR122023023401A2/pt unknown
- 2018-11-06 EP EP23208953.2A patent/EP4316522A3/en active Pending
- 2018-11-06 MX MX2020004694A patent/MX2020004694A/es unknown
- 2018-11-06 CN CN201880072032.9A patent/CN111295376B/zh active Active
- 2018-11-06 JP JP2020524298A patent/JP7269927B2/ja active Active
- 2018-11-06 DK DK18799511.3T patent/DK3707128T3/da active
- 2018-11-06 WO PCT/EP2018/080226 patent/WO2019091936A1/en active Application Filing
- 2018-11-06 AU AU2018363682A patent/AU2018363682B2/en active Active
- 2018-11-06 EP EP18799511.3A patent/EP3707128B1/en active Active
- 2018-11-06 UA UAA202003419A patent/UA127456C2/uk unknown
- 2018-11-06 US US16/761,670 patent/US20210177808A1/en active Pending
- 2018-11-06 KR KR1020207015898A patent/KR102606187B1/ko active IP Right Grant
- 2018-11-06 BR BR112020008853-6A patent/BR112020008853A2/pt unknown
- 2018-11-06 FI FIEP18799511.3T patent/FI3707128T3/fi active
- 2018-11-06 CA CA3081646A patent/CA3081646C/en active Active
-
2020
- 2020-05-04 CL CL2020001173A patent/CL2020001173A1/es unknown
- 2020-05-05 PH PH12020550555A patent/PH12020550555A1/en unknown
- 2020-05-22 CO CONC2020/0006257A patent/CO2020006257A2/es unknown
-
2024
- 2024-02-22 AU AU2024201169A patent/AU2024201169A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201150A1 (es) | Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| PE20161170A1 (es) | Composiciones farmaceuticas que comprenden azd9291 | |
| CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
| PE20160843A1 (es) | Pirrolidinonas herbicidas | |
| PE20161206A1 (es) | Derivado de urea o sal farmacologicamente aceptable del mismo | |
| CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
| PE20120691A1 (es) | Derivados de n1-sulfonil-5-fluoropirimidinona | |
| PE20191461A1 (es) | Compuestos amida para el tratamiento del vih | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20191652A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
| PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
| PE20091841A1 (es) | Inhibidores del virus de hepatitis c | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias |